Remsima (CT-P13) was approved by the European Commission in September 2013 for all the indications of the reference biological, Johnson & Johnson and Merck’s Remicade (infliximab), in the European Union. These include treatment of ankylosing spondylitis (AS), Crohn’s disease, psoriatic arthritis, psoriasis, rheumatoid arthritis and ulcerative colitis [2].

The study included 78 patients who began treatment with Remsima since March 2015. Of these, 25 were suffering from rheumatoid arthritis, 8 from psoriatic arthritis, 41 from spondyloarthropathies and 2 from severe uveitis. A total of 53 of these patients had already been treated with Remicade and 25 were ‘naïve’ to infliximab.

At nine months the overall survival rate was 86%, with only 23% of patients needing glucocorticoid use at nine months. The infusion period for Remsima had to be reduced to seven weeks or less in 22% of patients. Finally in 4 patients an optimization of treatment extending to more than 8 weeks was achieved. A small variation of CRP level (Δ < 5 mg/dL) at 9 months of initiation of Remsima treatment was also observed.

The authors concluded that ‘The results of safety and survival of biosimilar infliximab Remsima are similar to those shown in their pivotal trials PLANETRAS and PLANETAS’. They added that ‘these data support an increasingly widespread use of this biosimilar in any patient profile’.

Conflict of interest
The authors of the research paper [1] declared that there were no conflicts of interest.

Editor’s comment
It should be noted that data of the study presented in this article was published as an abstract/a press release. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

Related article
Biosimilars of infliximab

References
1. Rubio E, et al. AB0310 Prospective Study of 78 patients treated with infliximab biosimilar Remsima. Annal Rheum Dis. 2017;75(2).
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Mar 28]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.